Company updateCNBC-TV18
Cipla InvaGen facility gets USFDA No Action Indicated
Positive+18
GreyOak summary
Cipla's US subsidiary InvaGen received a 'No Action Indicated' classification from the USFDA following an inspection from October 19 to 22, 2026. This indicates no violations were observed, allowing the facility to continue selling approved drugs and pursue new filings.
What it affects
- CiplaCIPLAPositive +18
USFDA inspection resulted in No Action Indicated.Rolling sentiment Neutral -13
Source
Read the original at CNBC-TV18More Cipla news
- DRI searches Cipla Mumbai office and depotEconomic Times · Regulatory ·
- Senco Gold, Adani, BSE, Cipla shares in focusMint · Market wrap ·
- GIFT Nifty down 5 pts; BSE, Bajaj Finance, AEL, HDFC Life, Senco Gold, Cipla focusBusiness Today · Market wrap ·
- Stocks to Watch: Urban Company, Senco Gold, ARSS Infra, Capri Global, SML Mahindra, Lemon,Moneycontrol · Company update ·
- Deven Choksey prefers Sun Pharma, Cipla for fresh buying; sees upside in Indian ITCNBC-TV18 · Stock view ·